BioCentury | Aug 11, 2008
Clinical News

Ii-Key/HER2/neu cancer vaccine: Phase I started

Generex began an open-label Phase I trial to evaluate the AE37 vaccine in combination with a peptide vaccine in about 20 patients. The trial is being funded by the Mary Crowley Cancer Center. Generex Biotechnology...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

Cancer vaccines in development Company Product Description Indication Status Avax/Pro Vaccine/Australian Vaccine Tech M-Vax Autologous haptenized tumor cell vaccine Stage III and IV melanoma Compassionate use in France, Spain and Belgium; Ph I/II in U.S....
Items per page:
1 - 2 of 2